[{"id":"5eb63239-f0c2-440d-925c-994f2877adc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00740805","created_at":"2021-01-18T02:47:51.919Z","updated_at":"2025-02-25T13:47:58.987Z","phase":"Phase 1","brief_title":"Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00740805","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • veliparib (ABT-888) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 08/18/2008","start_date":" 08/18/2008","primary_txt":" Primary completion: 09/03/2021","primary_completion_date":" 09/03/2021","study_txt":" Completion: 10/22/2025","study_completion_date":" 10/22/2025","last_update_posted":"2025-02-20"},{"id":"94997e45-2dee-4e97-9985-6f9da960c39e","acronym":"BROCADE3","url":"https://clinicaltrials.gov/study/NCT02163694","created_at":"2021-01-17T17:32:00.170Z","updated_at":"2025-02-25T14:06:48.816Z","phase":"Phase 3","brief_title":"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer","source_id_and_acronym":"NCT02163694 - BROCADE3","lead_sponsor":"AbbVie","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 513","initiation":"Initiation: 04/08/2014","start_date":" 04/08/2014","primary_txt":" Primary completion: 04/05/2019","primary_completion_date":" 04/05/2019","study_txt":" Completion: 01/25/2024","study_completion_date":" 01/25/2024","last_update_posted":"2025-02-19"},{"id":"0a8d6efe-c307-457d-99f7-770545d57f94","acronym":"","url":"https://clinicaltrials.gov/study/NCT02631733","created_at":"2021-01-18T12:47:51.838Z","updated_at":"2025-02-25T15:25:24.826Z","phase":"Phase 1","brief_title":"Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors","source_id_and_acronym":"NCT02631733","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 05/31/2017","start_date":" 05/31/2017","primary_txt":" Primary completion: 11/21/2019","primary_completion_date":" 11/21/2019","study_txt":" Completion: 05/24/2023","study_completion_date":" 05/24/2023","last_update_posted":"2025-02-10"},{"id":"2e65ab02-5455-476f-a9fc-8810d776844a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01386385","created_at":"2021-01-19T08:29:02.253Z","updated_at":"2025-02-25T16:36:10.447Z","phase":"Phase 1/2","brief_title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01386385","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ERCC1 • XRCC1","pipe":" | ","alterations":" ERCC1 expression","tags":["ERCC1 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERCC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/20/2011","start_date":" 06/20/2011","primary_txt":" Primary completion: 05/26/2019","primary_completion_date":" 05/26/2019","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"8ba4b2c4-2d3e-460e-9a2f-77116f701fa8","acronym":"S1513","url":"https://clinicaltrials.gov/study/NCT02890355","created_at":"2021-01-18T14:11:10.280Z","updated_at":"2025-02-25T16:36:47.130Z","phase":"Phase 2","brief_title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02890355 - S1513","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CEACAM5","pipe":" | ","alterations":" HRD","tags":["BRCA1 • BRCA2 • HRD • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • veliparib (ABT-888) • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2025-02-06"},{"id":"e26650cf-8309-4e3f-ba36-361dadb2b1b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02595905","created_at":"2021-01-17T17:31:58.977Z","updated_at":"2025-02-25T16:36:40.508Z","phase":"Phase 2","brief_title":"Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases","source_id_and_acronym":"NCT02595905","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 333","initiation":"Initiation: 09/15/2016","start_date":" 09/15/2016","primary_txt":" Primary completion: 03/15/2025","primary_completion_date":" 03/15/2025","study_txt":" Completion: 03/15/2025","study_completion_date":" 03/15/2025","last_update_posted":"2025-02-06"},{"id":"597196ff-832d-47d8-abb2-6fd446401e06","acronym":"ACNS1721","url":"https://clinicaltrials.gov/study/NCT03581292","created_at":"2021-01-18T17:37:11.394Z","updated_at":"2025-02-25T16:52:13.824Z","phase":"Phase 2","brief_title":"Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations","source_id_and_acronym":"NCT03581292 - ACNS1721","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" IDH wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 11/06/2018","start_date":" 11/06/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 10/16/2025","study_completion_date":" 10/16/2025","last_update_posted":"2025-02-04"},{"id":"ae36f3a0-eb85-44ba-afee-09efb5463d1c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01434316","created_at":"2021-01-18T05:55:48.375Z","updated_at":"2025-02-25T16:51:08.574Z","phase":"Phase 1","brief_title":"Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT01434316","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • RAD51","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888) • dinaciclib (MK-7965)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 11/11/2011","start_date":" 11/11/2011","primary_txt":" Primary completion: 03/28/2023","primary_completion_date":" 03/28/2023","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2025-02-04"},{"id":"0a161a88-300c-46f6-886d-a1fdcd0ce1df","acronym":"","url":"https://clinicaltrials.gov/study/NCT02158507","created_at":"2021-01-18T10:02:31.452Z","updated_at":"2025-02-25T13:11:14.212Z","phase":"","brief_title":"Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer","source_id_and_acronym":"NCT02158507","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" HER-2 • PGR • BRCA1 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA mutation","tags":["HER-2 • PGR • BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lapatinib • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 09/04/2014","start_date":" 09/04/2014","primary_txt":" Primary completion: 07/22/2021","primary_completion_date":" 07/22/2021","study_txt":" Completion: 07/22/2021","study_completion_date":" 07/22/2021","last_update_posted":"2025-02-03"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"d7a0703a-8b1b-461b-a082-3de4e2b533f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03061188","created_at":"2021-01-17T18:03:06.477Z","updated_at":"2025-02-25T14:37:19.874Z","phase":"Phase 1","brief_title":"Phase I/Ib Study of Nivolumab \u0026 Veliparib in Patients With Advanced Solid Tumors \u0026 Lymphoma","source_id_and_acronym":"NCT03061188","lead_sponsor":"Northwestern University","biomarkers":" BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC","pipe":" | ","alterations":" MSI-H/dMMR • RAD50 mutation","tags":["BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAD50 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/23/2017","start_date":" 05/23/2017","primary_txt":" Primary completion: 03/11/2018","primary_completion_date":" 03/11/2018","study_txt":" Completion: 08/04/2020","study_completion_date":" 08/04/2020","last_update_posted":"2024-06-12"},{"id":"9a4116e1-774f-46ea-a206-c1400d303037","acronym":"A071102","url":"https://clinicaltrials.gov/study/NCT02152982","created_at":"2021-07-10T10:52:52.085Z","updated_at":"2024-07-02T16:35:02.746Z","phase":"Phase 2/3","brief_title":"Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","source_id_and_acronym":"NCT02152982 - A071102","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 447","initiation":"Initiation: 12/15/2014","start_date":" 12/15/2014","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-05-17"},{"id":"3996d836-38db-4e27-8cc0-e1b7578a424b","acronym":"REPAIR","url":"https://clinicaltrials.gov/study/NCT03044795","created_at":"2021-01-18T14:59:46.036Z","updated_at":"2024-07-02T16:35:06.249Z","phase":"Phase 2","brief_title":"Response to PARP Inhibitor Predicted by the RAD51 Assay","source_id_and_acronym":"NCT03044795 - REPAIR","lead_sponsor":"University Medical Center Groningen","biomarkers":" ER • BRCA1 • BRCA2 • BRCA • MUC16 • RAD51 • IL2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["ER • BRCA1 • BRCA2 • BRCA • MUC16 • RAD51 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 11/01/2020","primary_completion_date":" 11/01/2020","study_txt":" Completion: 11/01/2020","study_completion_date":" 11/01/2020","last_update_posted":"2024-05-03"},{"id":"5b878eb7-4cec-43f6-8253-c1aa01df90b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01351909","created_at":"2021-01-18T05:31:32.481Z","updated_at":"2024-07-02T16:35:15.320Z","phase":"Phase 1","brief_title":"Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT01351909","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA1 mutation • HER-2 negative • PGR positive • BRCA mutation • PARP1 expression","tags":["HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • HER-2 negative • PGR positive • BRCA mutation • PARP1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • veliparib (ABT-888) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/02/2011","start_date":" 05/02/2011","primary_txt":" Primary completion: 11/25/2016","primary_completion_date":" 11/25/2016","study_txt":" Completion: 03/07/2025","study_completion_date":" 03/07/2025","last_update_posted":"2024-03-11"},{"id":"956fd2ff-f11a-483d-b8e5-44b75b98a015","acronym":"","url":"https://clinicaltrials.gov/study/NCT01585805","created_at":"2021-01-17T17:23:09.794Z","updated_at":"2024-07-02T16:35:16.064Z","phase":"Phase 2","brief_title":"Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT01585805","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • PALB2 mutation • BRCA mutation","tags":["BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • PALB2 mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • veliparib (ABT-888) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 05/15/2012","start_date":" 05/15/2012","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-06"},{"id":"9570e8c9-b191-45c9-9417-d36759cc5e22","acronym":"","url":"https://clinicaltrials.gov/study/NCT01149083","created_at":"2021-01-18T04:34:27.095Z","updated_at":"2024-07-02T16:35:16.034Z","phase":"Phase 2","brief_title":"Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer","source_id_and_acronym":"NCT01149083","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 06/30/2010","start_date":" 06/30/2010","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-06"},{"id":"f0ba29c7-b73b-4be0-abe3-ad073e67bec5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01012817","created_at":"2021-01-18T03:58:12.492Z","updated_at":"2024-07-02T16:35:16.316Z","phase":"Phase 1/2","brief_title":"Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT01012817","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888) • topotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/03/2009","start_date":" 11/03/2009","primary_txt":" Primary completion: 01/13/2019","primary_completion_date":" 01/13/2019","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2024-03-05"},{"id":"da1ef968-77b6-450a-b8fd-792655c18e5e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01009788","created_at":"2021-01-18T03:57:07.007Z","updated_at":"2024-07-02T16:35:29.383Z","phase":"Phase 2","brief_title":"ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer","source_id_and_acronym":"NCT01009788","lead_sponsor":"Steven J Isakoff, MD, PhD","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 positive • BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 11/01/2009","start_date":" 11/01/2009","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-11-14"},{"id":"ec6fbe22-b1c8-44d5-90ef-3b484be78199","acronym":"","url":"https://clinicaltrials.gov/study/NCT01827384","created_at":"2021-01-18T08:07:17.493Z","updated_at":"2024-07-02T16:35:35.234Z","phase":"Phase 2","brief_title":"MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations","source_id_and_acronym":"NCT01827384","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • carboplatin • everolimus • temozolomide • adavosertib (AZD1775) • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 208","initiation":"Initiation: 01/07/2014","start_date":" 01/07/2014","primary_txt":" Primary completion: 06/19/2021","primary_completion_date":" 06/19/2021","study_txt":" Completion: 10/08/2021","study_completion_date":" 10/08/2021","last_update_posted":"2023-09-29"},{"id":"aa22a90c-7276-4cdd-9221-8ebf36da53d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00576654","created_at":"2021-01-18T02:06:27.098Z","updated_at":"2024-07-02T16:35:56.401Z","phase":"Phase 1","brief_title":"Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT00576654","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 12/05/2007","start_date":" 12/05/2007","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2023-02-06"},{"id":"d46a3905-b9b4-4342-9a8d-bb0f819c686b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03123211","created_at":"2021-01-18T15:23:20.041Z","updated_at":"2024-07-02T16:36:10.018Z","phase":"","brief_title":"Expanded Access to Veliparib","source_id_and_acronym":"NCT03123211","lead_sponsor":"AbbVie","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2022-05-24"},{"id":"765202f9-373b-4937-9117-32ae82f21dac","acronym":"","url":"https://clinicaltrials.gov/study/NCT02723864","created_at":"2021-01-18T13:19:41.499Z","updated_at":"2024-07-02T16:36:17.432Z","phase":"Phase 1","brief_title":"Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors","source_id_and_acronym":"NCT02723864","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RAD51 • NBN","pipe":"","alterations":" ","tags":["RAD51 • NBN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • veliparib (ABT-888) • berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 12/15/2020","primary_completion_date":" 12/15/2020","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-02-08"},{"id":"eef9d4a0-3d75-4945-9763-78e585ead519","acronym":"","url":"https://clinicaltrials.gov/study/NCT01506609","created_at":"2021-01-17T17:26:20.717Z","updated_at":"2024-07-02T16:36:22.558Z","phase":"Phase 2","brief_title":"Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer","source_id_and_acronym":"NCT01506609","lead_sponsor":"AbbVie","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • temozolomide • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 294","initiation":"Initiation: 01/23/2012","start_date":" 01/23/2012","primary_txt":" Primary completion: 12/13/2018","primary_completion_date":" 12/13/2018","study_txt":" Completion: 09/02/2020","study_completion_date":" 09/02/2020","last_update_posted":"2021-10-25"},{"id":"f32ce9fe-6272-4bb5-920b-97a75b8b98c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02985658","created_at":"2021-01-18T14:41:09.712Z","updated_at":"2024-07-02T16:36:27.611Z","phase":"","brief_title":"Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer","source_id_and_acronym":"NCT02985658","lead_sponsor":"University of Washington","biomarkers":" HER-2 • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["HER-2 • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • veliparib (ABT-888) • vinorelbine tartrate"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2021-07-21"}]